initial coding process. This study characterizes inaccuracies in coding practices that result in incorrect sarcoma surgical diagnostic codes and tumor registry data at a high-volume health care center. Identification of coding practice errors has implications for the validity of larger oncology databases.
Methods | The Brigham and Women's Hospital Institutional Review Board approved the study and waived the need for patient consent. Patients who underwent resection of primary or recurrent sarcoma between January 1, 2012, and December 31, 2016, by 5 sarcoma surgeons (including C.P.R.) were identified using prospectively collected data from Brigham and Women's Hospital and Dana-Farber Cancer Institute. Demographic data were not collected. Results | During the study period, 2715 patients with soft-tissue and bone oncologic cases were treated by 3 surgical oncologists (1856 cases) and 2 orthopedic oncologists (859 cases). Of these, 1237 patients (855 treated by surgical oncologists, 382 treated by orthopedic oncologists) had a sarcoma diagnosis confirmed by pathologic findings.
On the basis of ICD-9 and ICD-10 codes, 764 of 1237 patients (61.8%) had cases that were accurately coded as sarcoma, 208 of 1237 patients (16.8%) had a nononcologic diagnosis, and 265 of 1237 patients (21.4%) had an organ sitebased malignancy code; 487 of 855 patients (57.0%) treated by surgical oncologists and 277 of 382 patients (72.5%) treated by orthopedic oncologists had cases that were accurately coded. Organ-confined sarcoma was commonly coded with a nonsarcoma, organ-site ICD-9 or ICD-10 code (Table) . For instance, 49 of 156 (31.4%) gastric gastrointestinal stromal tumor cases and 24 of 46 (52.2%) breast angiosarcoma cases were coded as gastric and breast cancer, respectively (Figure) .
Based on ICD-O-3 codes from the Dana-Farber Cancer Institute tumor registry during an overlapping 4-year period, 631 of 1055 patients (59.8%) had cases that were accurately coded, 26 of 1055 patients (2.5%) had cases that were coded with an other cancer diagnosis, and 398 of 1055 patients (37.7%) had cases that were not listed in the registry.
Discussion | This study emphasizes that the vague nature of definitions for diseases can lead to coding inaccuracies that can be propagated through data sets, which is an issue that possibly extends beyond any single institution. Our study has several limitations. First, the coding inaccuracies as identified in this study may be specific to our institution. Our findings may not be generalizable to all sarcoma centers, and confirmation from other institutions is needed. However, tumor registrars are trained uniformly by American Joint Committee on Cancer guidelines, which raises concern that this issue could be widespread. Consequently, national data sets may not be as comprehensive or useful as expected for studying population-based outcomes for sarcoma. Nevertheless, properly framed questions may still be valid within the limitations of such data sets. Potential reasons for our findings include the heterogeneity, number of histologic subtypes, and variable nomenclature of sarcoma, which renders accurate characterization of cases challenging. 5,6 Sarcoma may be inaccurately classified on the basis of the organ site rather than on the basis of the pathologic findings. National databases-including the National Inpatient Sample; the American College of Surgeons' and American Cancer Society's National Cancer Database; the Centers for Disease Control and Prevention National Program of Cancer Registries; and the Surveillance, Epidemiology, and End Results Program-that rely on International Classification of Diseases codes are vulnerable to limitations attributable to inaccurate coding. Gross underestimation in coding data representing sarcoma resections may also contribute to skewed market forecasts. Our findings, if validated by others, suggest that the number of sarcoma cases may be higher than that reported by studies that use these data sets. At present, the net effect of coding errors is unknown. Discussions among surgeons, pathologists, coders, and tumor registrars about how to specify sarcomas are encouraged. To the Editor We read with great interest the article by BarrosoSousa et al. 1 The analysis includes 38 randomized clinical trials comprising 7551 patients and suggests that patients receiving combination therapy are at increased risk of thyroid dysfunction and hypophysitis. In general, it is an excellent and welldesigned meta-analysis that provides more precise data on the incidence of endocrine dysfunction among patients receiving immune checkpoint inhibitor regimens. However, we would like to address some potential questions regarding the content of this article. Primarily, the selection of databases bears incompleteness that may contribute to a wrong conclusion. They only retrieved articles from PubMed, whereas Embase, Cochrane Library, and ClinicalTrials.gov were not searched. This might result in bias in a meta-analysis by finding studies that show larger estimates. Besides, similar meta-analyses published in JAMA Oncology have provided information retrieved from the other databases (Embase, Cochrane Library, PsycINFO, and CINAHL). 2 The incomplete inclusion of literature may result in deficient data and even wrong conclusions.
3,4
The database was searched for articles published on or before July 18, 2016. However, new articles were published between July 2016 and October 2017. An updated retrieval after manuscript revision and before manuscript acceptance is lacking. Second, as the authors say, the use of metaanalytic techniques to pool published summary data is associated with the possibility of heterogeneity of included studies, whereas we did not find the reasons accounting for it. Is it from race, dosage, or other reasons? Moreover, a systematic quality assessment might give an evaluation of included studies and account partly for the source of heterogeneity. However, quality assessment for the large sample size of 38 clinical trials is missing.
Despite some concerns regarding the work of BarrosoSousa et al, 1 we are impressed by their original contribution to the research on endocrine dysfunction among patients receiving immune checkpoint inhibitor regimens. We are interested in the updated database retrieval and further reply.
Tian Li, MD, PhD Shuai Jiang, MD, PhD Yang Yang, MD, PhD
In Reply We appreciate the interest and comments by Li and colleagues regarding our article, 1 which compared the incidence of endocrine adverse events following treatment with immune checkpoint regimens in a systematic review and metaanalysis of published trial reports. Our work included a total of 38 clinical trials retrieved from the PubMed database evaluating the use of checkpoint inhibitors for the treatment of advanced solid tumors, resulting in a total of 7551 patients who were eligible for this meta-analysis. Thus, it is unlikely that the data regarding the incidence of thyroid toxic effects or hypophysitis would differ significantly if further studies were added. We recognize that after the date of the database search (July 18, 2016), new articles have been published, and an update of our work with new studies and additional information sources would be welcome. By including newly reported clinical trials, such efforts may help to establish the incidence and risks of less frequent endocrinopathies, such as primary adrenal insufficiency and type 1 diabetes. Moreover, in our meta-analysis we did not include other types of immunotherapy combination regimens, such as programmed cell death/programmed cell death ligand 1 inhibitors plus chemotherapy or combinations with antiangiogenic drugs. A work including these regimens would be of interest now that some combinations have been approved, 2 and many are under review for approval, for the treatment of different advanced solid tumors.
As stated in our article, 1 one of the limitations of our work is that we conducted a meta-analysis at the study level, and we could not establish additional potential risk factors possibly associated with the development of endocrine adverse events. In our analyses, dosage was not a modifier of drug effects and exploratory analyses of other patient characteristics, including age, sex, and smoking status, failed to identify 
